A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with locally advanced or metastatic breast cancer and other solid tumors.

Trial Details

NCT ID
NCT06609187
Phase
PHASE1
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • GNC-077
Locations (sample)
  • Beijing, Beijing Municipality, China

Key Eligibility Criteria

  • Able to understand the informed consent form, voluntarily participate in and sign the informed consent form;
  • Gender is not limited;
  • Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib);
  • Locally advanced or metastatic breast cancer and other solid tumors;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →